Bahija Jallal (file photo)

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahi­ja Jal­lal’s crew at TCR pi­o­neer Im­muno­core says they have nailed down a promis­ing set of piv­otal da­ta for their lead drug in a front­line set­ting for a sol­id tu­mor. And they are fram­ing this ear­ly in­ter­im read­out as the con­vinc­ing snap­shot they need to prove that their plat­form can de­liv­er on a string of break­through ther­a­pies now in the clin­ic or planned for it.

In ad­vance of the Mon­day an­nounce­ment, Jal­lal and R&D chief David Berman took some time to walk me through the first round of Phase III da­ta for their lead TCR de­signed to treat rare, front­line cas­es of metasta­t­ic uveal melanoma that come with a grim set of sur­vival ex­pec­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.